Conditional survival in glioblastoma: The evolution of prognostic factors over time
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70285 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Timothy Mueller und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Conditional survival provides insights into the evolution of prognosis over time and reveals changing associations of prognostic factors during disease progression. Data on the temporal evolution of prognostic factors in glioblastoma remain scarce. We analyzed 315 patients with IDH‐wildtype glioblastoma from a prospectively collected registry (01/2008–06/2017). Our primary outcome was 12‐month conditional survival (CS), defined as the probability of surviving the next 12 months given survival for “ s ” months. This analysis was conducted at five landmarks ( s = 0, 6, 12, 18, 24) for baseline prognostic factors, including tumor volume compartments. 12‐month conditional survival estimates at s = 0, 6, 12, 18, and 24 months from diagnosis were 0.51 (95% CI 0.45–0.56), 0.46 (95% CI 0.39–0.52), 0.41 (95% CI 0.33–0.49), 0.43 (95% CI 0.33–0.52), and 0.56 (95% CI 0.42–0.67), respectively. At diagnosis ( s = 0), 12‐month survival estimates varied significantly with age >60 at diagnosis, preoperative tumor rim volume >20 cm 3 , absence of O 6 ‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation, postoperative KPS ≥70, residual postoperative tumor >1 cm 3 , or biopsy only. Residual tumor volume mainly influences survival in the initial months following surgery, while MGMT promoter methylation and age remain significant predictors beyond this period. These findings may refine stratification strategies in recurrent glioblastoma trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Neurosurgery, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
- Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Pediatric Neurosurgery, Kinderspital Zürich, Children's University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- Department of Neurosurgery, LMU University Hospital, München, LMU Munich, Germany.
- Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
ORCID-Profile: Timothy Mueller, Jonathan Weller
Zitieren
APA
Mueller, T., Vasella, F., Velz, J., Voglis, S., Akeret, K., Padevit, L., Schubert, M., Weller, J., Brüningk, S., Rushing, E., Sarnthein, J., Gramatzki, D., Häni, L., Raabe, A., Zeitlberger, A. M., Bozinov, O., Le Rhun, E., Weller, M., Regli, L., & Neidert, M. C. (2025). Conditional survival in glioblastoma: The evolution of prognostic factors over time. International Journal of Cancer. https://doi.org/10.1002/ijc.70285
Vancouver
Mueller T, Vasella F, Velz J, Voglis S, Akeret K, Padevit L, et al. Conditional survival in glioblastoma: The evolution of prognostic factors over time. International Journal of Cancer. 2025. doi:10.1002/ijc.70285
BibTeX
@article{Mueller2025,
author = {Mueller, Timothy and Vasella, Flavio and Velz, Julia and Voglis, Stefanos and Akeret, Kevin and Padevit, Luis and Schubert, Morton and Weller, Jonathan and Brüningk, Sarah and Rushing, Elisabeth and Sarnthein, Johannes and Gramatzki, Dorothee and Häni, Levin and Raabe, Andreas and Zeitlberger, Anna M and Bozinov, Oliver and Le Rhun, Emilie and Weller, Michael and Regli, Luca and Neidert, Marian C},
title = {Conditional survival in glioblastoma: The evolution of prognostic factors over time},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70285}
}
EUVIMED